



15<sup>th</sup> May, 2017

<p>To, The Manager, Listing Department, National Stock Exchange of India Ltd. "Exchange Plaza", C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.</p> <p>Ref. : (i) Symbol – DISHMAN (ii) Series – EQ</p>	<p>To, Department of Corporate Services Bombay Stock Exchange Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.</p> <p>Ref.: Scrip Code No. : 532526</p>
---	--

**SUB: INTIMATION OF CONFERENCE CALL**

Dear Sir,

This is to inform that pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, the Company has arranged Conference Call with Investors on Wednesday, 17<sup>th</sup> May, 2017 at 4.00 P.M. IST to discuss the financial result and performance of the Company for the quarter and year ended on 31<sup>st</sup> March, 2017.

Kindly take the same on your record.

Thanking You,

Yours faithfully,  
For, Dishman Pharmaceuticals and Chemicals Limited

  
Shrima Dave  
Company Secretary



**Note:** As informed to the Stock Exchanges earlier, Scheme of Arrangement and Amalgamation amongst Dishman Pharmaceuticals and Chemicals Ltd. ("DPCL"), Carbogen Amcis (India) Limited ("CAIL") and Dishman Care Limited ("DCL") has become effective from the date of filing of certified copy of the order of Hon'ble High Court of Gujarat dated 16<sup>th</sup> December, 2016 with the Office of Registrar of Companies, Gujarat i.e. w.e.f. 17<sup>th</sup> March, 2017. Accordingly, DPCL has been merged into CAIL and Board of Directors of DPCL has been appointed as Board of Directors of CAIL.

**Dishman Pharmaceuticals and Chemicals Limited**

Registered Office: Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad – 380 009 India.

Tel: +91 (0) 79 26443053 / 26445807 Fax: +91 (0) 79 26420198

Email: dishman@dishmangroup.com Web: www.dishmangroup.com

**Government Recognised Export House**

CIN NO L24230GJ1983PLC006329